{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG000","title":"Part 2 (Open-Label Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"ITT Population. Only those participants who entered into Part 2 (Open-label eltrombopag-only phase) were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 24 of Part 2","title":"Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}